Relapsed/Refractory Chronic Lymphocytic Leukemia: The Evolving Role of BTK Inhibitors

episode

Keeping Current CME not yet transcribed

▲ 0

Transcript

This episode hasn't been transcribed yet Upvotes decide what gets transcribed next — 0 so far. Sign in to upvote

Related

recent transcribed audio

The Biggest Criticism Of Taylor Swift Debunked & The Secret Messages Behind Her New Songs 52 min · 28 Sep 2026 · The Spill

NPR News: 09-28-2026 1AM EDT 5 min · 28 Sep 2026 · NPR News Now

The Jerker Episode 54 min · 28 Sep 2026 · Distractible

1AM ET 09/28/2026 Newscast 3 min · 28 Sep 2026 · Fox News Hourly Update

"TEARS OF JOY!" | Brave Knights Stun World to Book GF vs Roosters 2h 21m · 28 Sep 2026 · Bloke In A Bar

Take Heed How You Hear 5 min · 28 Sep 2026 · Things Unseen with Sinclair B. Ferguson

Report any issue

Source

Recorded06 Dec 2023

Publisherkeepingcurrentcme.libsyn.com ↗

Handlerec:4299759

Show notes

Did you know that the National Comprehensive Cancer Network (NCCN) guidelines now include an investigational noncovalent BTK inhibitor for the treatment of relapsed/refractory CLL? Credit available for this activity expires: 12/05/24 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/998747?ecd=bdc_podcast_libsyn_mscpedu

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Sign in